Astellas Pharma, Inc. (ALPMY)
15.95
+0.18
(+1.14%)
USD |
OTCM |
Oct 23, 16:00
Astellas Pharma Enterprise Value : 30.73B for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 30.73B |
| October 22, 2026 | 30.41B |
| October 21, 2026 | 30.25B |
| October 20, 2026 | 29.89B |
| October 19, 2026 | 29.28B |
| October 16, 2026 | 29.26B |
| October 15, 2026 | 28.87B |
| October 14, 2026 | 27.86B |
| October 13, 2026 | 27.94B |
| October 12, 2026 | 27.86B |
| October 09, 2026 | 27.86B |
| October 08, 2026 | 27.60B |
| October 07, 2026 | 27.67B |
| October 06, 2026 | 27.51B |
| October 05, 2026 | 27.61B |
| October 02, 2026 | 27.81B |
| October 01, 2026 | 28.03B |
| September 30, 2026 | 28.08B |
| September 29, 2026 | 28.67B |
| September 28, 2026 | 28.94B |
| September 25, 2026 | 29.42B |
| September 24, 2026 | 28.81B |
| September 23, 2026 | 29.14B |
| September 22, 2026 | 29.66B |
| September 21, 2026 | 29.41B |
| Date | Value |
|---|---|
| September 18, 2026 | 29.35B |
| September 17, 2026 | 29.37B |
| September 16, 2026 | 28.61B |
| September 15, 2026 | 28.78B |
| September 14, 2026 | 28.76B |
| September 11, 2026 | 28.24B |
| September 10, 2026 | 27.63B |
| September 09, 2026 | 28.01B |
| September 08, 2026 | 28.47B |
| September 04, 2026 | 29.12B |
| September 03, 2026 | 29.87B |
| September 02, 2026 | 29.25B |
| September 01, 2026 | 28.85B |
| August 31, 2026 | 28.64B |
| August 28, 2026 | 28.55B |
| August 27, 2026 | 28.94B |
| August 26, 2026 | 29.07B |
| August 25, 2026 | 29.32B |
| August 24, 2026 | 29.10B |
| August 21, 2026 | 29.10B |
| August 20, 2026 | 28.96B |
| August 19, 2026 | 29.23B |
| August 18, 2026 | 27.99B |
| August 17, 2026 | 27.83B |
| August 14, 2026 | 28.53B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Takeda Pharmaceutical Co., Ltd. | 91.54B |
| Daiichi Sankyo Co., Ltd. | 31.63B |
| Eisai Co., Ltd. | 9.101B |
| Chugai Pharmaceutical Co., Ltd. | 65.07B |
| Santen Pharmaceutical Co., Ltd. | 3.297B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 889.54M |
| Revenue (Quarterly) | 4.022B |
| Total Expenses (Quarterly) | 3.133B |
| EPS Diluted (Quarterly) | 0.4955 |
| Gross Profit Margin (Quarterly) | 75.29% |
| Profit Margin (Quarterly) | 22.12% |
| Earnings Yield | 8.22% |
| Operating Earnings Yield | 11.17% |
| Normalized Earnings Yield | 8.220 |